Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Anlotinib in ES-SCLC
NCT07501169Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, anlotinib in small cell lung cancer (SCLC), sponsored by Sichuan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecananlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07501169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501169.